Loading...
XSHE300003
Market cap2.66bUSD
Jan 27, Last price  
10.37CNY
1D
-2.35%
1Q
-14.44%
Jan 2017
-42.16%
IPO
-10.29%
Name

Lepu Medical Technology Beijing Co Ltd

Chart & Performance

D1W1MN
XSHE:300003 chart
P/E
15.31
P/S
2.41
EPS
0.68
Div Yield, %
4.57%
Shrs. gr., 5y
0.84%
Rev. gr., 5y
4.65%
Revenues
7.98b
-24.78%
175,338,190298,984,733393,879,358565,197,407770,100,945919,846,2401,015,920,0791,303,267,8311,668,636,9552,768,717,4633,467,748,2334,537,642,6566,356,304,7927,795,529,3868,038,667,54010,659,734,87510,609,442,0807,979,899,318
Net income
1.26b
-42.91%
63,600,462149,725,515201,368,062292,212,135410,482,721473,157,671403,273,290361,645,473423,192,551520,890,606679,255,737899,085,3301,218,692,8991,725,306,1911,801,932,5321,719,324,5782,203,779,3741,258,200,337
CFO
990m
-64.51%
58,317,51961,365,102188,594,285239,785,236374,248,775291,197,594264,962,979329,757,071348,316,884436,460,676691,890,147913,132,5411,500,508,9371,990,255,0632,089,699,3043,061,991,8512,790,709,307990,359,814
Dividend
Sep 20, 20240.142 CNY/sh
Earnings
Mar 28, 2025

Profile

Lepu Medical Technology (Beijing) Co., Ltd. develops, produces, and sells medical devices and equipment. The company offers cardiovascular interventional products, such as coronary stents and balloons, catheters, guide wires, introducer sheaths, tourniquets, inflation devices, and PCI accessories; structural heart diseases products, including occluders, vascular plugs, delivery systems, and mechanical heart valves; cardiac rhythm management products, which include pacemakers, equipment, leads, and electrophysiology; off-pump coronary artery bypass grafting surgical cardiology products; and PTA balloons and guide wires peripheral interventional products. It also provides critical care products, such as vascular access products, needle free connectors, blood samplers, and pressure transducers; floor and suspended type digital subtraction angiography systems; in vitro diagnostic equipment and biomarkers; hemodialysis catheters and hollow fiber dialyzers; and general surgery products, including surgical staplers and endo surgery accessories. In addition, the company offers cardiovascular system drugs, such as antithrombotic, hypolipidemic, antihypertensive, antianginal, and heart failure treatment; ß-lactamase antibiotics and antifungal antimicrobial drugs; central nervous system drugs comprises painkillers and antidepressants; gastric/duodenal ulcer and chronic liver disease treatment drugs; respiratory system drugs; hypoproteinemia drugs; and activating blood circulation drugs. Further, it provides precision medicine, ECG telemonitoring, and cardiovascular disease consulting and management center services; medical S&T incubation and equity investment, and medical financial services; consultation, online pharmacy, and household medical equipment services; smart devices; and specialized hospital services for cardiovascular diseases, as well as involved in the co-construction of Cath lab. The company was founded in 1999 and is headquartered in Beijing, China.
IPO date
Oct 30, 2009
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
7,979,899
-24.78%
10,609,442
-0.47%
Cost of revenue
4,985,175
7,198,412
Unusual Expense (Income)
NOPBT
2,994,724
3,411,030
NOPBT Margin
37.53%
32.15%
Operating Taxes
262,147
367,094
Tax Rate
8.75%
10.76%
NOPAT
2,732,577
3,043,936
Net income
1,258,200
-42.91%
2,203,779
28.18%
Dividends
(635,057)
(487,986)
Dividend yield
2.12%
1.17%
Proceeds from repurchase of equity
(75,244)
(1)
BB yield
0.25%
0.00%
Debt
Debt current
1,039,743
1,940,845
Long-term debt
3,642,937
2,563,513
Deferred revenue
3,711
183,748
Other long-term liabilities
1
1
Net debt
(2,383,780)
(3,519,921)
Cash flow
Cash from operating activities
990,360
2,790,709
CAPEX
(844,669)
Cash from investing activities
(1,882,477)
Cash from financing activities
(292,918)
412,749
FCF
1,222,757
2,463,001
Balance
Cash
4,495,959
5,744,493
Long term investments
2,570,501
2,279,785
Excess cash
6,667,465
7,493,806
Stockholders' equity
13,597,555
13,974,914
Invested Capital
15,438,019
13,069,364
ROIC
19.17%
25.02%
ROCE
13.43%
16.42%
EV
Common stock shares outstanding
1,857,638
1,816,900
Price
16.16
-29.65%
22.97
1.50%
Market cap
30,019,433
-28.07%
41,734,190
2.01%
EV
29,157,106
39,438,550
EBITDA
3,508,284
3,899,502
EV/EBITDA
8.31
10.11
Interest
170,645
188,775
Interest/NOPBT
5.70%
5.53%